{
    "clinical_study": {
        "@rank": "124576", 
        "arm_group": [
            {
                "arm_group_label": "azacitidine with birinapant", 
                "arm_group_type": "Active Comparator", 
                "description": "Azacitidine 75 mg/m2 IV on days 1-5, 8 & 9 OR days 1-7 and birinapant 13  mg/m2 IV twice a week (days 1 & 4) for 3 out of 4 weeks"
            }, 
            {
                "arm_group_label": "Azacitidine and placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Azacitidine 75mg/m2 IV days 1-5, 8 & 9 OR days 1-7 and placebo IV twice a week (days 1 & 4) for 3 out of 4 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized double blind placebo controlled study of  azacitidine with or without\n      birinapant in subjects with higher risk Myelodysplastic syndrome  myelomonocytic leukemia\n      (CMMoL) who are na\u00efve, to azacitidine therapy. Pre-clinical and mechanistic studies support\n      that azacitidine may modulate pathways that enable birinapant-mediated anti-tumor activity."
        }, 
        "brief_title": "Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Myelodysplastic Syndrome (MDS)", 
            "Chronic Myelomonocytic Leukemia (CMML)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myelomonocytic, Chronic", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Leukemia, Myelomonocytic, Acute"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized double blind placebo controlled study of  azacitidine with or without\n      birinapant in subjects with higher risk Myelodysplastic syndrome  myelomonocytic leukemia\n      (CMMoL)\n\n      The primary purpose of this study  is :\n\n      -To compare the relative effect of azacitidine plus birinapant versus azacitidine plus\n      placebo on response rate in patients with higher-risk MDS or CMMoL.\n\n      The secondary purpose of this study is to compare effect of azacitidine plus birinapant\n      relative to azacitidine with placebo on:\n\n        -  Hematologic improvement\n\n        -  Relapse free survival\n\n        -  Time to respond\n\n        -  Change in transfusion requirements\n\n        -  Duration of response\n\n        -  Overall survival\n\n        -  Adverse events"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "key Inclusion Criteria:\n\n          -  Morphologically confirmed diagnosis of MDS/CMMoL based on 1 of the following:\n\n             a. French-American-British (FAB) classifications:\n\n          -  Refractory anemia with excess blasts (RAEB)\n\n          -  CMMoL with \u226420%% myeloblasts in the bone marrow with peripheral monocytosis\n\n          -  b. World Health Organization (WHO) Classifications:\n\n          -  RAEB-1\n\n          -  RAEB-2\n\n          -  CMMoL-1\n\n          -  CMMoL-2\n\n          -  International prognostic score (IPSS) of Intermediate 2 (1.5-2.0 points) or High\n             (\u22652.5 points); a score of Intermediate 1 (0.5-1.0 points) is  allowable in the\n             setting of \u22655% myeloblasts in the bone marrow\n\n          -  Previously untreated with hypomethylating agents for MDS/CMMoL\n\n          -  Performance status of 0 or 1 by the ECOG scale, and estimated life expectancy of at\n             least 3 months.\n\n          -  Adequate renal and liver function\n\n          -  Female subjects of childbearing potential must have a negative serum pregnancy test\n             at screening  within 96 hours prior to the first study dose.\n\n          -  Female subjects of childbearing potential and male subjects with partners of\n             childbearing potential should ensure use of a highly effective method of birth\n             control as defined by the investigator, for example, those which result in a low\n             failure rate (i.e., less than 1% per year) when used consistently and correctly\n             during the study and for a period of 3 months following the last dose of any drug\n             administered during the study.\n\n          -  In France, a subject will be eligible for inclusion in this study only if either\n             affiliated to or a beneficiary of a social security category.\n\n        Key Exclusion Criteria:\n\n          -  Relapsed or refractory MDS.\n\n          -  Hypoplastic MDS.\n\n          -  Secondary MDS.\n\n          -  Acute myeloid leukemia (AML).\n\n          -  Participated in any interventional study within 4 weeks of randomization.\n\n          -  Received any hematopoietic growth factors for at least 14 days prior to screening.\n\n          -  Prior malignancy or secondary malignancy within the prior 2 years (except in situ\n             cervical cancer, squamous cell carcinoma or basal cell carcinoma of the skin).\n\n          -  Planned hematopoietic stem-cell transplant.\n\n          -  known diagnosis of human immunodeficiency virus or chronic active Hep B or C.\n\n          -  Uncontrolled hypertension\n\n          -  Impaired cardiac function, uncontrolled cardiac arrhythmias despite medications, or\n             clinically significant cardiac disease\n\n          -  QT interval corrected for heart rate (QTcB) more than 480 msec\n\n          -  Lack of recovery of prior adverse events to Grade \u22641 severity (National Cancer\n             Institute Common Terminology Criteria for Adverse Events version 4) (except alopecia)\n             due to therapy administered prior to the initiation of study drug dosing.\n\n          -  Nursing or pregnant.\n\n          -  Known allergy or hypersensitivity to any of the formulation components\n\n          -  Any concurrent disease and/or medical condition that, in the opinion of the\n             Investigator, would prevent the subject's participation.\n\n          -  History of cranial nerve palsy.\n\n          -  Being treated with anti-TNF therapies."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "158", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147873", 
            "org_study_id": "TL32711-0094", 
            "secondary_id": "2014-001719-37"
        }, 
        "intervention": [
            {
                "arm_group_label": "azacitidine with birinapant", 
                "intervention_name": "birinapant", 
                "intervention_type": "Drug", 
                "other_name": "TL32711"
            }, 
            {
                "arm_group_label": [
                    "azacitidine with birinapant", 
                    "Azacitidine and placebo"
                ], 
                "intervention_name": "Azacitidine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Azacitidine and placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Azacitidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "MDS", 
            "CMML", 
            "myelodysplastic syndrome", 
            "chronic myelomonocytic leukemia", 
            "TL32711", 
            "TL32711-0094", 
            "azacitidine", 
            "birinapant", 
            "higher risk", 
            "naive", 
            "double blind", 
            "placebo", 
            "placebo controlled", 
            "randomized"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia", 
        "other_outcome": {
            "measure": "exploratory translational biomarkers for antitumor effect", 
            "safety_issue": "No", 
            "time_frame": "30 days"
        }, 
        "overall_contact": {
            "email": "minal.mehta@tetralogicpharma.com", 
            "last_name": "Minal Mehta", 
            "phone": "610-889-9900", 
            "phone_ext": "111"
        }, 
        "overall_contact_backup": {
            "email": "judy.schnyder@tetralogicpharma.com", 
            "last_name": "Judy Schnyder", 
            "phone": "610-889-9900", 
            "phone_ext": "151"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Czech Republic: State Institute for Drug Control", 
                "Italy: The Italian Medicines Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Response Rate", 
            "safety_issue": "No", 
            "time_frame": "participants will be followed for until disease progression an expected average of 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147873"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Hematologic improvement", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for until disease progression an expected average of 1 year"
            }, 
            {
                "description": "According to modified IWG 2006 criteria", 
                "measure": "Relapse  free survival", 
                "safety_issue": "No", 
                "time_frame": "An expected average of 2 year post last study dose"
            }, 
            {
                "measure": "Time to respond", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for until disease progression an expected average of 1 year"
            }, 
            {
                "measure": "Change in transfusion requirements", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for until disease progression an expected average of 1 year"
            }, 
            {
                "description": "According to modified IWG 2006 criteria", 
                "measure": "duration of response", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for until disease progression an expected average of 1 year"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "An expected average of 2 year post last study dose"
            }, 
            {
                "measure": "Adverse events profile", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be monitored for adverse events throughout the treatment period and  during follow up period"
            }
        ], 
        "source": "TetraLogic Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TetraLogic Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}